Kymera Therapeutics, Inc.
KYMR
$43.87
$2.054.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.82% | 7.31% | -13.23% | -48.56% | 13.38% |
| Total Depreciation and Amortization | 1.76% | 3.07% | 0.00% | 2.53% | 32.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.55% | 11.17% | -6.64% | 9.31% | -25.33% |
| Change in Net Operating Assets | 104.94% | -669.50% | -265.71% | 92.61% | -107.92% |
| Cash from Operations | 24.34% | -28.11% | -23.10% | -16.89% | -8.45% |
| Capital Expenditure | -48.82% | 50.11% | -595.24% | 104.03% | 36.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 23.70% | -29.38% | 144.03% | -876.49% | 106.29% |
| Cash from Investing | 23.46% | -29.10% | 143.49% | -1,108.06% | 104.73% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -37.91% | 5.46% | 54.29% | -82.10% | -21.38% |
| Issuance of Common Stock | 45,901.50% | -98.30% | -87.51% | 14,160.71% | -99.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 95,142.64% | -90.67% | -98.90% | 17,670.40% | -99.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 912.05% | -417.07% | -77.82% | 266.32% | -57.41% |